Τρίτη 27 Αυγούστου 2019


Few Oncologists Suggest Health Promotion to Cancer Survivors
Oncologists expressed concern that health promotion could distress or overwhelm cancer survivors (Source: The Doctors Lounge - Oncology)
MedWorm Cancer & Oncology News
1m
Childhood Cancer Survivors Struggle With Heart Troubles
Title: Childhood Cancer Survivors Struggle With Heart TroublesCategory: Health NewsCreated: 8/26/2019 12:00:00 AMLast Editorial Review: 8/27/2019 12:00:00 AM (Source: MedicineNet Cancer General)
MedWorm Cancer & Oncology News
1m
Men Should be Included in Breast Cancer Clinical Trials: FDA
Title: Men Should be Included in Breast Cancer Clinical Trials: FDACategory: Health NewsCreated: 8/26/2019 12:00:00 AMLast Editorial Review: 8/27/2019 12:00:00 AM (Source: MedicineNet Cancer General)
MedWorm Cancer & Oncology News
1m
Does Erdafitinib Show Clinical Benefit in Locally Advanced or Metastatic Urothelial Carcinoma?
Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations. (Source: CancerNetwork)
MedWorm Cancer & Oncology News
1m
Standard Adjuvant Chemotherapy Compared to Capecitabine in Early Breast Cancer
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer  recurrence-free survival. (Source: CancerNetwork)
MedWorm Cancer & Oncology News
1m
Quiz: Incidence and Screening in Prostate Cancer
How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out. (Source: CancerNetwork)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
MedWorm Cancer & Oncology News
1m
New connections: Targeting PRMTs in cancer
Drugs that block protein methyltransferases may be effective in RNA splicing–mutant cancers. (Source: Signal Transduction Knowledge Environment)
MedWorm Cancer & Oncology News
1m
Nomograms for predicting the survival rate for cervical cancer patients who undergo radiation therapy: a SEER analysis
Future Oncology, Ahead of Print. (Source: Future Oncology)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
MedWorm Cancer & Oncology Research
14h
DAPT, a γ-Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling
In this study, the molecular signaling pathway related to GHoma was investigated by proteomics and transcriptomics. The differentially expressed proteins and genes were significantly enriched in Extracellular Matrix-Receptor Interactions, Notch Signaling, Basal Cell Carcinoma Signaling, JAK-STAT3, Wnt Signaling and Glioblastoma Multiforme Signaling by Ingenuity Pathway Analysis. Furthermore, the Notch2/Delta-like canonical Notch ligand (DLL) signaling pathway was identified to be associated with...
MedWorm Cancer & Oncology Research
14h
Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials
ConclusionsTreatment with aMASCT plus apatinib was safe and effective for the management of advanced solid tumors. (Source: Cancer Immunology, Immunotherapy)
MedWorm Cancer & Oncology Research
14h
The Use of (Network) Meta-Analysis in Clinical Oncology
Meta-analysis is important in oncological research to provide a more reliable answer to a clinical research question that was assessed in multiple studies but with inconsistent results. Pair-wise meta-analysis can be applied when comparing two treatments at once, whereas it is possible to compare multiple treatments at once with network meta-analysis (NMA). After careful systematic review of the literature and quality assessment of the identified studies, the added value of meta-analysis should...
MedWorm Cancer & Oncology Research
14h
Cancers, Vol. 11, Pages 1254: 3D Quantitative and Ultrastructural Analysis of Mitochondria in a Model of Doxorubicin Sensitive and Resistant Human Colon Carcinoma Cells
Authors: Claudia Moscheni Emil Malucelli Sara Castiglioni Alessandra Procopio Clara De Palma Andrea Sorrentino Patrizia Sartori Laura Locatelli Eva Pereiro Jeanette A. Maier Stefano Iotti Drug resistance remains a major obstacle in cancer treatment. Because mitochondria mediate metabolic reprogramming in cancer drug resistance, we focused on these organelles in doxorubicin sensitive and resistant colon carcinoma cells. We employed soft X-ray cryo nano-tomography...
MedWorm Cancer & Oncology Research
14h
MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma
Cancer cell plasticity plays critical roles in both tumorigenesis and tumor progression. Metastasis-associated protein 3 (MTA3), a component of the nucleosome remodeling and histone deacetylase (NuRD) complex and multi-effect coregulator, can serve as a tumor suppressor in many cancer types. However, the role of MTA3 in tongue squamous cell cancer (TSCC) remains unclear although it is the most prevalent head and neck cancer and often with poor prognosis. By analyzing both published datasets and clinical...
MedWorm Cancer & Oncology Research
14h
Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges
In the last decades, immunologists have started to consider intracellular metabolism in relationship with dynamics and functions of immune cells, especially when it became clear that microenvironmental alterations were associated with immune dysfunctions. Regulatory T cells (Tregs) are equipped with a variety of immunological and metabolic sensors, and encompass circulating as well as tissue-resident cells, being therefore particularly susceptible to microenvironmental cues. Moreover, Tregs undergo...
MedWorm Cancer & Oncology Research
14h
Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma
Treating head and neck cancer patients with systemic therapy is challenging because of tumor related, patient related and treatment related factors. In this review, we aim to summarize the current standard of care in the curative and palliative setting, and to describe best practice with regard to structural requirements, procedures and monitoring outcome. Treatment advice for individual head and neck cancer patients should be discussed within a multidisciplinary team. Cisplatin is the drug of...
MedWorm Cancer & Oncology Research
14h
PD-L1 Distribution and Perspective for Cancer Immunotherapy —Blockade, Knockdown, or Inhibition
Cancer immunotherapy involves in blocking the interactions between PD-1/PD-L1 immune checkpoint with antibodies and has shown unprecedented positive outcomes in clinics. Particularly, the PD-L1 antibody therapy has shown the efficiency in blocking membrane PD-L1 and efficacy in treating some advanced solid cancers. However, this therapy has limited effects on many solid tumors, suspecting to be revelent to PD-L1 located in other cellular compartments, where they play additional roles and are associated...
MedWorm Cancer & Oncology Research
14h
Identification of a Specific Gene Module for Predicting Prognosis in Glioblastoma Patients
Conclusions: This study demonstrated the potential application of weighted gene co-expression network analysis-based gene prognostic model for predicting survival outcome of glioblastoma patients. (Source: Frontiers in Oncology)
MedWorm Cancer & Oncology Research
14h
Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy
Publication date: Available online 26 August 2019Source: Progress in Materials ScienceAuthor(s): Xing Guo, Xiao Wei, Zi Chen, Xiaobin Zhang, Guang Yang, Shaobing ZhouAbstractTo achieve highly effective treatment to diseases, successful delivery of drugs with a carrier into the specific organelles (nucleus, mitochondria, lysosomes, etc.) is of great importance. Targeted delivery based on nanoparticle (NP)-based drug delivery systems (NDDSs) is mainly focused on cell-membrane targeting. In this review...
MedWorm Cancer & Oncology Research
14h
Fabrications of magnetic responsive hydroxyapatite platform: In vitro release of chemo drug for cancer therapy
In this study, multifunctional platform consists of cobalt ferrite magnetite particles fixed in a hydroxyapatite have been synthesized by microwave assisted wet precipitation method. The synthesized samples were studied by X-ray diffraction, Fourier transform infrared spectroscopy, field emission scanning electron microscopy, transmission electron microscopy and vibrating sample magnetometer. TEM results showed that hydroxyapatite embedded cobalt ferrite platform calcined at 900 °C have core-shell...
MedWorm Cancer & Oncology Research
14h
A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA ( −) prostate cancer specific therapy
The selectively accumulate in tumor site and completely release drug within cancer cells great limit the therapeutic effect of nano-drug delivery system. Moreover, absence of appropriate biomarker is one of th... (Source: Journal of Nanobiotechnology)
MedWorm Cancer & Oncology Research
14h
Microenvironmental Regulation of Long Noncoding RNA LINC01133 Promotes Cancer ‐Stem‐Cell‐like Phenotypic Traits in Triple‐Negative Breast Cancers
LINC01133 responds to mesenchymal stem/stromal cell ‐regulated miR‐199a/214‐FOXP2 pathway and upregulates the expression of the pluripotency master regulator KLF4 to drive cancer‐stem‐cell‐like phenotypic traits. AbstractThe fibrotic tumor microenvironment is a critical player in the pathogenesis of triple ‐negative breast cancers (TNBCs), with the presence of fibroblastic infiltrates particularly correlating with tumors that are clinically advanced. On this front, we previously demonstrated that...
MedWorm Cancer & Oncology Research
14h
Insights into the management of older patients with multiple myeloma.
Authors: Anderson KC PMID: 31449504 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Update on transfusion-related acute lung injury.
Authors: Toy P PMID: 31449502 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Next-generation sequencing for the general cancer patient.
Authors: Avila M, Meric-Bernstam F Abstract Next-generation sequencing is a novel method of DNA sequencing that has become a cornerstone of precision oncology. This sequencing method detects differences in specific DNA sequences between a sample and a reference genome or matched normal DNA. In addition to single-nucleotide variants, other insertions, deletions, copy number changes, and fusions may be drivers of cancer growth, and thus represent therapeutic opportunities. As a result, genomic...
MedWorm Cancer & Oncology Research
16h
Risk factors for and clinical management of venous thromboembolism during pregnancy.
Authors: Rybstein MD, DeSancho MT Abstract Venous thromboembolism (VTE), which comprises deep vein thrombosis and pulmonary embolism, is one of the leading causes of non-obstetric maternal death in the United States. Physiologic and anatomic changes associated with pregnancy set the stage for a hypercoagulable state. In addition, other risk factors-including those associated with certain fetal characteristics such as low birth weight or stillbirth-have been correlated with an increased...
MedWorm Cancer & Oncology Research
16h
Management of rare epithelial ovarian cancers.
Authors: Gershenson DM PMID: 31449512 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Authors: George DJ PMID: 31449503 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
MedWorm Cancer & Oncology Research
16h
PSMA PET/CT for staging and treatment of prostate cancer.
Authors: Hofman M PMID: 31449501 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Improving the disclosure of conflicts of interest in medicine.
Authors: Arnold D PMID: 31449505 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Management of advanced phase myeloproliferative neoplasms.
This article reviews management considerations for the advanced-phase MPNs (MPN-AP and MPN-BP), with a special focus on MPN-AP, and highlights novel experimental therapies. PMID: 31449507 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
When to use triplet chemotherapy as first-line treatment in metastatic colorectal cancer.
Authors: Cremolini C PMID: 31449510 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Highlights in breast cancer from the 2019 American Society of Clinical Oncology annual meeting.
Authors: PMID: 31449508 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
MedWorm Cancer & Oncology Research
16h
A rational approach to the development of drug combinations in thoracic oncology.
Authors: Camidge DR PMID: 31449509 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Authors: Seymour J PMID: 31449511 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
MedWorm Cancer & Oncology Research
16h
Imaging of prostate cancer with positron emission tomography.
Authors: Zimmerman ME, Meyer AR, Rowe SP, Gorin MA Abstract Prostate cancer is most commonly imaged through a combination of magnetic resonance imaging, x-ray computed tomography, and 99mTc-methylene diphosphonate bone scan. These conventional imaging modalities, however, suffer from limited sensitivity and specificity for the detection of disease. This can lead to disease understaging and the improper selection of treatment. To address this problem, a variety of novel radiotracers for...
MedWorm Cancer & Oncology Research
16h
Carotid dosimetry after re-irradiation with 131Cs permanent implant brachytherapy in recurrent, resected head and neck cancer.
Conclusions: Carotid artery doses from 131Cs are reported. Vascularized tissue flaps should be considered when planning 131Cs brachytherapy. PMID: 31447900 [PubMed] (Source: Journal of Contemporary Brachytherapy)
MedWorm Cancer & Oncology Research
16h
Psychometric assessment of the Italian version of the melanoma module (SCNS-M12-Ita) of the Supportive Care Needs Survey (SCNS-SF34).
CONCLUSIONS: The study demonstrated that the SCNS-M12-Ita is a valid and reliable instrument for assessing the supportive care needs of patients with melanoma. PMID: 31448687 [PubMed - as supplied by publisher] (Source: Tumori)
MedWorm Cancer & Oncology Research
16h
Workload of breast image-guided intensity-modulated radiotherapy delivered with TomoTherapy.
CONCLUSION: This treatment times analysis on the use of IMRT for BC might be useful to organize and improve the workflow efficiency in RT facilities. PMID: 31446853 [PubMed - as supplied by publisher] (Source: Tumori)
MedWorm Cancer & Oncology Research
16h
Assessment of biological parameters in head and neck cancer based on in vivo distribution of 18F-FDG-FLT-FMISO-PET/CT images.
CONCLUSION: Our preliminary results suggest worse prognosis in patients with higher heterogeneity values of primary tumor in proliferation and hypoxia images and combination of metabolic and volumetric parameters in TLG and its equivalent and heterogeneity of primary tumor seems to be a prognostic factor. PMID: 31446858 [PubMed - as supplied by publisher] (Source: Tumori)
MedWorm Cancer & Oncology Research
16h

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
CONCLUSIONS: Metastases burden, LDH levels, and RLC are independent baseline characteristics associated with outcome in patients with melanoma receiving anti-PD-1. Further investigations are needed to clarify if evaluation of these parameters can translate into clinical strategy and apply to patient selection. PMID: 31446882 [PubMed - as supplied by publisher] (Source: Tumori)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media...
MedWorm Cancer & Oncology Research
16h
High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer.
CONCLUSION: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors. PMID: 31446852 [PubMed - as supplied by publisher] (Source: Tumori)
MedWorm Cancer & Oncology Research
16h
LncRNA HEIH regulates cell proliferation and apoptosis through miR-4458/SOCS1 axis in triple-negative breast cancer
In conclusion, HEIH functions as an oncogenic lncRNA that is overexpressed in TNBC and associated with clinical progression, and regulates TNBC cell proliferation and apoptosis through miR-4458/SOCS1 axis. (Source: Human Cell)
MedWorm Cancer & Oncology Research
16h
Micronodules Detected on Lung Cancer Screening CT Scans.
Authors: Arenberg D PMID: 31445728 [PubMed - in process] (Source: Ann Oncol)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
MedWorm Cancer & Oncology Research
17h
Correction to: Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.
Authors: PMID: 31449458 [PubMed - in process] (Source: Circulation)
MedWorm Cancer & Oncology Research
17h
Dermatologist-level classification of malignant lip diseases using a deep convolutional neural network.
CONCLUSION: DCNNs can classify lip diseases at a level similar to dermatologists. This will help unskilled physicians discriminate between benign and malignant lip diseases. This article is protected by copyright. All rights reserved. PMID: 31449661 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
MedWorm Cancer & Oncology Research
17h
Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma.
Conclusion: Elevated NLR alone and in combination with hyponatremia at time of initial RCC diagnosis and at time of RCC recurrence are associated with poor prognosis. Combining these two prognostic markers yield a stronger association than NLR considered alone. This may impact prognostic prediction and its related therapeutic strategy. PMID: 31448981 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
MedWorm Cancer & Oncology Research
17h
Increased Risk of All Cardiovascular Disease Subtypes Among Childhood Cancer Survivors: Population-Based Matched Cohort Study.
Authors: Khanna A, Pequeno P, Gupta S, Thavendiranathan P, Lee DS, Abdel-Qadir H, Nathan PC PMID: 31446776 [PubMed - as supplied by publisher] (Source: Circulation)
MedWorm Cancer & Oncology Research
17h
Reviewing the Evidence that Polypectomy Prevents Cancer.
Authors: Kahi CJ Abstract Colonoscopic polypectomy is fundamental to effective prevention of colorectal cancer. Polypectomy reduces colorectal cancer incidence and mortality by altering the natural history and progression of precancerous precursor polyps. Epidemiologic data from the United States, where colorectal cancer rates have been steadily declining in parallel with screening efforts, provide indisputable evidence about the effectiveness of polypectomy. Randomized controlled trials...
MedWorm Cancer & Oncology Research
18h
Assessing the Quality of Polypectomy and Teaching Polypectomy.
Authors: Duloy AM, Keswani RN Abstract Ineffective polypectomy technique may lead to incomplete polyp resection, high complication rates, interval colorectal cancer, and costly referral to surgery. Despite its central importance to endoscopy, training in polypectomy is not standardized nor has the most effective training approach been defined. Polypectomy competence is rarely reported and quality metrics for this skill are lacking. Use of tools and measurements to assess polypectomy outcomes...
MedWorm Cancer & Oncology Research
18h
Surgery Versus Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Large Polyps: Making Sense of When to Use Which Approach.
Authors: Fukami N Abstract Endoscopic resection for large colorectal lesion is effective and cost-saving than surgery. Piecemeal resections are often effective if applied meticulously but endoscopic submucosal dissection (ESD) allows meritorious removal of large lesions in one piece. For rectal lesions, transanal endoscopic microsurgery or transanal minimally invasive surgery offers more radical transmural resection but ESD is also effective for removal of complex rectal lesions. Surgical...
MedWorm Cancer & Oncology Research
18h
Endoscopic Assessment of the Malignant Potential of the Nonpolypoid (Flat and Depressed) Colorectal Neoplasms: Thinking Fast, and Slow.
This article provides information on assessment of the malignant potential of colorectal neoplasms. It takes a modern approach on the topic and integrates relevant information that aligns with the thinking process. The theory of thinking fast (reflex) and slow (rational) is used. By doing so, it is hoped that the learning process can be expedited and practiced immediately. The focus is on preresection assessment of nonpolypoid colorectal neoplasms. Assessment of polypoid, sessile-serrated adenoma/polyp,...
MedWorm Cancer & Oncology Research
18h
How to Learn and Perform Endoscopic Submucosal Dissection and Full-Thickness Resection in the Colorectum in the United States.
This article reviews challenges and methods in learning ESD in the United States and provides a primer on performing ESD and full-thickness resection in the colorectum. PMID: 31445688 [PubMed - in process] (Source: Clinical Colorectal Cancer)
MedWorm Cancer & Oncology Research
18h
How to Perform Wide-Field Endoscopic Mucosal Resection and Follow-up Examinations.
Authors: Bourke M, Jideh B Abstract Wide-field endoscopic mucosal resection (EMR) is the primary management option for noninvasive laterally spreading colorectal lesions. It has been proved to be safe, highly effective, efficient, and cost-effective. Careful lesion interrogation before resection is essential because it provides essential information, including the risk of submucosal invasive disease. Adjuvant thermal ablation to the post-EMR defect margin has recently been shown to substantially...
MedWorm Cancer & Oncology Research
18h
Outcomes of Inpatient Administration of Restricted Antineoplastic Medications at a Large Academic Medical Institution.
Conclusion: In this single-center study, approximately one-third of the outpatient-restricted medications were not continued upon discharge. The findings suggest that our informal approval process could result in the suboptimal use of formulary outpatient-restricted medications for oncology and hematology indications. A more formalized request process might lead to the more effective utilization of these medications. PMID: 31447536 [PubMed] (Source: P and T)
MedWorm Cancer & Oncology Research
18h
American Society of Clinical Oncology 2019.
Authors: Alexander W PMID: 31447537 [PubMed] (Source: P and T)
MedWorm Cancer & Oncology Research
18h

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου